Rahat Chaudhry
Pulmonary Disease · McKeesport, PANPI 1033173489
Payments from drug & device makers
Across 117 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$604
- GSK$600
- Regeneron Healthcare Solutions, Inc.$139
- Mylan Specialty L.p.$120
- Genentech USA, Inc.$102
- Novartis$98
- plus $558 from 13 others
What the payments were for
- Food & beverage$2,12696%
- Education$954%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 28 | $604 |
| GSK | 36 | $600 |
| Regeneron Healthcare Solutions, Inc. | 6 | $139 |
| Mylan Specialty L.p. | 6 | $120 |
| Genentech USA, Inc. | 4 | $102 |
| Novartis | 5 | $98 |
| Sanofi | 5 | $98 |
| Boehringer Ingelheim | 5 | $96 |
| AbbVie | 3 | $58 |
| Teva Pharmaceuticals USA, Inc. | 4 | $55 |
| Philips North America LLC | 3 | $54 |
| CSL Behring | 2 | $40 |
| Grifols USA, LLC | 2 | $38 |
| Sunovion Pharmaceuticals Inc. | 3 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Resmed Corp | 1 | $20 |
| Advanced Respiratory, Inc | 1 | $19 |
| Mallinckrodt Enterprises LLC | 1 | $18 |
| Electromed, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$116
How this compares
$2,221 in reported general payments places this provider in the 55th percentile of 703 pulmonary disease providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GlassiaAlpha-1-Proteinase Inhibitor | 15 | $168,144 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in McKeesport
- Gerard CrinerPhiladelphia$18.2M
- Sandeep Bansaldu Bois$8.9M
- David WheelerPhiladelphia$7.7M
- Steven AlbeldaPhiladelphia$5.5M
- Paul SimonelliDanville$2.1M
- Kevin GibsonPittsburgh$1.3M
- Frank SciurbaPittsburgh$1.2M
- Joseph PilewskiPittsburgh$1M
- Steven DuncanPittsburgh$995K
- Tariq CheemaPittsburgh$907K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.